2-(2,7-diaza-spiro[3.5]non-2-ylmethyl)-5-(5-fluoro-1H-indol-4-yl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine | 1093075-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 2-(2,7-diaza-spiro[3.5]non-2-ylmethyl)-5-(5-fluoro-1H-indol-4-yl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine
• 英文别名: 4-[2-(2,7-diazaspiro[3.5]nonan-2-ylmethyl)-5-(5-fluoro-1H-indol-4-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine
• CAS: 1093075-30-9
• 化学式: C₂₅H₂₈FN₇OS
• 分子量: 493.608
• InChiKey: QRVNSGBAIJIFKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE
  申请人：Hancox Timothy Colin

  公开号：US20100190769A1

  公开（公告）日：2010-07-29

  Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R 1 and R 2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R is H or C 1 -C 6 alkyl; and R is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  式(I)的噻唑嘧啶化合物：其中W代表噻唑环；R1和R2与它们所附着的N原子一起形成下式(IIa)的基团：其中A是一个环系统；m为0、1或2；R为H或C1-C6烷基；R为未取代或取代的吲哚基团；以及其药学上可接受的盐是PI3K的抑制剂，并且选择性地作用于p110δ同工型，这是一种Ia类PD激酶，而不是其他Ia类和Ib类激酶。这些化合物可用于治疗由PI3激酶导致的异常细胞生长、功能或行为引起的疾病和障碍，例如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。
• THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2158207A1

  公开（公告）日：2010-03-03
• US7893060B2
  申请人：——

  公开号：US7893060B2

  公开（公告）日：2011-02-22
• US8168633B2
  申请人：——

  公开号：US8168633B2

  公开（公告）日：2012-05-01
• [EN] THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE<br/>[FR] THIAZOLOPYRIMIDINES ET LEUR UTILISATION COMME INHIBITEURS DE LA PHOSPHATIDYLINOSITOL-3 KINASE (PI3K)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008152390A1

  公开（公告）日：2008-12-18

  [EN] Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; and R4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110d isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
  [FR] La présente invention concerne des thiazolopyrimidines de formule (I) : dans laquelle W représente un cycle thiazole; R1 et R2 forment, conjointement avec l'atome d'N auquel ils sont liés, un groupe ayant la formule (Ha) : dans laquelle A représente : un système cyclique; m est égal à 0, 1 ou 2; R3 représente H ou alkyle en C1- C6; et R4 représente un groupe indole substitué ou non; et leurs sels pharmaceutiquement acceptables, qui sont des inhibiteurs de la PI3K et sont sélectifs de l'isoforme p110d, qui est une PD kinase de classe Ia, par rapport aux deux autres kinases de classe Ia et Ib. Les composés peuvent être utilisés pour traiter des maladies et des troubles résultant d'une croissance, fonction ou comportement cellulaire anormaux associés à la PI3 kinase tels que cancer, troubles immunitaires, maladie cardiovasculaire, infection virale, inflammation, des troubles du métabolisme ou de la fonction endocrine et troubles neurologiques.